Legend Biotech ($LEGN): CARVYKTI Grew 50% And Half A Cohort Is Five Years Progression-Free

01 Bull, base and bear scenarios

What Would Falsify This Reading

The reading set out above is that CARVYKTI is compounding fast enough to carry a company that only books part of its economics, while LB2501 remains an option rather than a value. That reading is checkable. Each of the following would damage it, and each can be verified against a filing rather than against an opinion.

• CARVYKTI growth decelerates sharply. Net trade sales grew 50 per cent year on year in the second quarter of 2026, to roughly $657 million, with the United States up 32 per cent and the rest of the world up 128 per cent. The ex-US number is doing the heavy lifting and comes off a smaller base. A quarter in which total growth drops toward the US rate would say the international launch curve has flattened, and the whole earnings argument depends on that curve.
• The gap between collaboration revenue and product sales widens. The $657 million is sold by the Johnson & Johnson collaboration, not booked by Legend. Legend recognised $326.1 million of collaboration revenue and $61.4 million of licence and other revenue against a cost of collaboration revenue of $136.0 million. If the share reaching Legend falls, or if the cost line grows faster than the revenue it sits against, headline franchise growth will stop translating into Legend earnings.
• Another equity raise arrives below the June price. The June 23, 2026 offering sold 7.7 million ADS at $29.35 for $212.4 million net. At the September 30 close of $19.89 the shares sit about 32 per cent below that price. Cash and time deposits of $964.6 million at June 30 do not force a raise, but a further offering priced under the last one would confirm that this company still funds itself in the equity market on the market’s terms rather than its own.
• LB2501 does not hold up in a larger cohort. The dataset is six high-dose patients: complete response in five, objective response in all six, and a median follow-up of 2.2 months. Nothing in a cohort that size survives contact with a larger one automatically. A dose expansion showing lower complete-response rates, shorter durability, weaker CAR-T persistence or a heavier cytokine-release profile would remove the platform argument that sits behind the shares.
• The safety file gets heavier rather than lighter. The United States prescribing information already carries a boxed warning and monitoring requirements for cytokine release syndrome, neurologic toxicities, haemophagocytic lymphohistiocytosis and macrophage activation syndrome, prolonged and recurrent cytopenias and secondary malignancies, with immune effector cell-associated enterocolitis added in 2025 at a company-cited 1.2 per cent incidence. A label change, a new class warning or a restriction on where the product can be administered would cut directly into the site expansion that is driving the sales line.

None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.

02 September 25 update: durability, safety and the financial baseline

September 25 clinical update. The durability signal comes from CARTITUDE-2 Cohort A, a small, nonrandomized Phase 2 cohort. It must be assessed alongside the new safety follow-up, rather than treated as a cure claim or a new CARTITUDE-4 Phase 3 result. Results and safety.

The headline numbers require careful labeling. The $657 million represents sales made by the Johnson & Johnson/Legend collaboration to the market. It is not Legend’s reported revenue. Legend recognized $326.1 million of collaboration revenue plus $61.4 million of license and other revenue, producing $387.5 million in total revenue.

LB2501 was highlighted again in the Q2 release, but the six-patient dose-level-two data were first presented in June 2026. They are not a new August clinical readout. At the highest reported dose, all six patients responded and five achieved a complete response; median follow-up was just 2.2 months. All responses were ongoing at the cutoff.

Leadership changed immediately before the quarter update. Ying Huang resigned as CEO and director effective July 24. Alan Bash, previously president of CARVYKTI, became interim CEO pending the successor search, which concluded with Ingrid Zhang’s appointment on September 15. The company said the resignation did not result from a disagreement over operations, policies, financials or controls.

Two filings since then set the governance calendar. On August 18 the company gave notice that its Annual General Meeting was scheduled for September 24, 2026 at its Bridgewater, New Jersey offices, and filed the proxy materials with it. The notice is signed by Alan Bash as interim chief executive, which confirms that the permanent appointment had not been made as of that date. A Form 4 filed the same day reports an award of 4,908 restricted share units to Bash on August 14, at no cost, taking the total reported against his name to 35,142. The units vest in three equal instalments on July 27 of 2027, 2028 and 2029, and only if he is still with the company, so the figure is not a holding of shares already owned. It is a grant rather than an open-market purchase, and its size is what one would expect for an interim appointment rather than a permanent one.

June’s equity offering is now part of the capital structure: 7.7 million ADS at $29.35 generated $212.4 million of net proceeds. The underwriters’ option for another 1.155 million ADS expired unexercised on July 17.

03 Investment thesis in one page

What the business is becoming

Legend is no longer best analyzed as a pre-revenue biotech with a single binary approval event. CARVYKTI is an approved, rapidly scaling global franchise, the collaboration produced quarterly operating income, and the balance sheet holds nearly $1 billion of cash and time deposits. The valuation now depends on commercial execution, manufacturing throughput, partner economics and lifecycle expansion as much as on clinical probability.

What still makes it a biotech

The company remains concentrated in one marketed therapy and one partner relationship. CARVYKTI is a complex autologous product with serious safety warnings, manufacturing logistics and reimbursement friction. Most follow-on programs are early, while the most eye-catching next-platform result comes from six high-dose patients with a median 2.2 months of follow-up.

04 How CARVYKTI economics reach Legend

CARVYKTI is jointly developed and commercialized with Janssen, part of Johnson & Johnson. The collaboration structure means three different measures must not be mixed:

The $56 million Janssen milestone makes Q2 total revenue less recurring than the trade-sales growth rate alone suggests. For quarter-to-quarter modeling, collaboration revenue and its cost, license milestones, R&D and sales/distribution expense should be separated.

Legend also carries $156.4 million of current collaboration interest-bearing advanced funding: $79.2 million principal and $77.2 million accrued interest, with a 7.13% effective rate. It has no specified maturity and is expected to be recouped by Janssen from Legend’s share of collaboration profits or milestones within twelve months. It is economically relevant even though it is not a conventional bank loan.

05 Q2 2026 income statement and cash-flow quality

For the first half, total revenue was $692.6 million and operating income was $7.9 million, but net loss remained $21.1 million. Operating cash use was $106.0 million. That prevents one strong quarter from being mistaken for a fully mature free-cash-flow profile.

The tax line carries uncertainty. The transfer-pricing advance pricing arrangement with the Chinese tax authority had not been formally executed at quarter-end; the final liability could differ materially. Investors should therefore avoid applying a simple annualized Q2 earnings multiple without normalizing milestone and tax items.

06 CARVYKTI commercial engine

CARVYKTI is a BCMA-directed autologous CAR-T therapy approved in the United States for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent, when disease is lenalidomide-refractory. Earlier-line access materially expands the eligible population compared with the original late-line setting.

Q2 net trade sales grew 32% in the United States and 128% outside the United States. Availability expanded to 348 treatment sites in 19 markets, including Ireland. The ex-U.S. growth rate indicates that geographic rollout is becoming a second engine rather than a marginal royalty stream.

Manufacturing remains central. Autologous CAR-T requires patient-specific collection, transport, manufacturing, release and reinfusion. Installed capacity at the Raritan expansion is designed for up to 10,000 patients annually, but installed capacity is not the same as released doses, treated patients or profitable throughput. Investors should watch vein-to-vein time, out-of-specification rates, slot availability and site activation.

Competition: two different near-term tests

Gilead disclosed FDA acceptance of the anito-cel BLA for fourth-line or later relapsed/refractory multiple myeloma, with a December 23, 2026 PDUFA target. Anito-cel remains investigational; a review date is not approval. Its potential entry would add another BCMA CAR-T option, initially in a later-line population than CARVYKTI’s current U.S. indication. The approved label, safety profile, manufacturing capacity and launch execution would matter more than a headline comparison of response rates. Gilead, February 23, 2026.

Separately, Johnson & Johnson reported Phase 3 MonumenTAL-6 topline results on July 23, 2026. In patients with one to four prior lines, TECVAYLI plus TALVEY reduced the risk of progression or death by 89% and the risk of death by 62% versus investigator-selected standard therapy (EPd or PVd). These are relative risk reductions within that trial, not a comparison with CARVYKTI. The combination was investigational in this setting. Its off-the-shelf delivery creates a different treatment option to follow; the result does not show superiority to CAR-T or revenue payable to Legend. J&J, July 23, 2026.

07 CARVYKTI clinical value and safety burden

What the five-year cohort shows, and what it does not

In the September 25 report, median progression-free survival was 60.5 months; five-year overall survival was 69.2%, with median overall survival not reached. Since the earlier approximately 30-month analysis, one new acute myeloid leukemia case and two additional deaths, from progressive disease and a new cancer, were reported. No new CAR-T-related neurotoxicity was reported. Legend’s September 25 release, filed with the SEC.

The study register identifies CARTITUDE-2 as an open-label, multicohort Phase 2 study. Cohort A included patients after one to three previous treatment lines who were lenalidomide-refractory. A descriptive long-term result in 20 patients cannot show how every patient will fare or quantify an advantage over an untreated comparison group: this cohort has no randomized comparator. Progression-free survival and overall survival answer different questions, so their percentages are not interchangeable. The release gives a follow-up duration but does not disclose a calendar data cutoff. CARTITUDE-2 registry, NCT04133636.

For the commercial thesis, durable treatment-free intervals could support the therapy’s clinical value. They do not translate mechanically into higher quarterly revenue, broader reimbursement or unlimited manufacturing capacity. Continued safety surveillance remains necessary; the underlying evidence does not show a causal explanation for the cancer reported during follow-up. The trial result and the operating results below therefore remain separate parts of the assessment.

CARTITUDE-4 moved CARVYKTI earlier in treatment and supports an overall-survival advantage. At 33.6 months of median follow-up, the reported overall-survival hazard ratio was 0.55; the earlier primary PFS analysis reported a hazard ratio of 0.41. These are powerful randomized results in the studied population.

The benefit comes with material risk. The U.S. prescribing information carries a boxed warning and extensive monitoring requirements for cytokine release syndrome, neurologic toxicities, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, prolonged and recurrent cytopenias and secondary malignancies. In 2025 the label also added immune effector cell-associated enterocolitis. Company analyses cited a 1.2% incidence, but low frequency does not eliminate seriousness.

The long-term opportunity depends on continuing to show that earlier use improves outcomes enough to justify referral, logistics and risk. CARTITUDE-5 follows transplant-ineligible newly diagnosed patients; CARTITUDE-6 follows transplant-eligible newly diagnosed patients; CARTITUDE-10 continues enrollment in another frontline setting.

08 LB2501: why the signal matters and why it is fragile

LB2501 is an in vivo CD19/CD20 dual-target CAR-T candidate built on Legend’s third-generation, replication-incompetent TaVec lentiviral platform. Instead of removing a patient’s cells for ex vivo engineering, the vector is designed to generate CAR-T cells inside the body. The study does not use lymphodepletion. On October 15, 2026 the FDA cleared Legend’s U.S. IND for LB2501, supporting a planned U.S. Phase 1/2 study of safety, tolerability, pharmacokinetics and preliminary efficacy; the company describes it as the first known dual-targeting in vivo CAR-T therapy to receive FDA IND clearance. Source If scalable, that approach could compress the manufacturing chain and make cell therapy more accessible.

At dose level two, six of six evaluable patients responded and five achieved complete responses. All responses were ongoing at the cutoff. Across twelve treated patients, no dose-limiting toxicities, serious adverse events, ICANS or deaths were reported. Cytokine release syndrome occurred in 66.7% and infusion reactions in 75%, all Grade 2 or lower. Related Grade 3 or higher events were limited to lymphocyte and neutrophil decreases. CAR-T cells were detectable for as long as 116 days.

The key next data are cohort size, duration of complete response, progression-free survival, vector kinetics, persistence, shedding/insertional safety, reproducibility across sites and whether avoiding lymphodepletion remains feasible. These variables determine whether LB2501 is a platform or a memorable six-patient snapshot.

09 Pipeline map beyond CARVYKTI

The October 2026 corporate presentation also lists LB2505, an in vivo BCMA program for relapsed/refractory multiple myeloma, with status “Initiating.” Slide 21 identifies it as a Phase 1 investigator-initiated trial in China and marks it as subject to the Legend/J&J collaboration and license agreement. “Initiating” does not show that patients have been dosed or that clinical results exist. Legend Biotech investor relations document.

LB2102 supplied the other meaningful 2026 readout. In twenty patients with DLL3-positive solid tumors, overall ORR was 20% and disease-control rate 70%. At dose level three or higher, ORR was 28.6% and DCR 78.6%. CRS occurred in 30%, all Grade 2 or lower; ICANS occurred in 15%, including one Grade 3 event. The dataset is early and single-arm.

Novartis paid $100 million upfront for LB2102 rights outside the current U.S. Phase 1 responsibilities. Legend is eligible for up to $1.01 billion in milestones and high-single-digit to low-teens royalties. Those maximum milestones are not receivables and are not worth their face value in a valuation.

10 Balance sheet, financing and dilution

The first-half cash-flow statement shows why headline cash requires context. Investing cash use was $288.0 million, including $241.5 million of net time-deposit purchases, $31.5 million for Janssen collaboration assets and $15.0 million for property and equipment. Financing cash inflow was $166.5 million, mainly the offering. Operating cash use was $106.0 million.

Management says current resources should extend beyond 2026. That is credible on the disclosed balance sheet, but it is not a no-dilution promise. The June offering increased the ordinary share count by 15.4 million shares, or 7.7 million ADS. Per-share value creation must therefore outpace equity issuance and stock-based compensation.

11 Management, ownership and governance

Ingrid Zhang became CEO on September 15, following her role as Chief Commercial Officer for Novartis International. Alan Bash, interim CEO from July 24, resumes the President, CARVYKTI role. The company release is the source for this transition.

GenScript Biotech was disclosed as beneficial owner of 174.5 million ordinary shares, or 47.2%, as of February 15, 2026. That is a dated percentage from before the June offering, not a current post-offering percentage. The relationship makes GenScript the dominant shareholder and creates both alignment and related-party/governance considerations.

The CEO transition is a risk because it occurred during rapid global scaling. It is not evidence of accounting trouble: the company explicitly said the resignation was not caused by disagreement about operations, policies, financials or controls. Investors should judge the transition through executive retention, execution under the newly appointed CEO, manufacturing performance and whether pipeline priorities remain coherent.

12 Competitive landscape

CARVYKTI competes with other BCMA-directed therapies and with different treatment modalities. ABECMA is the other approved BCMA CAR-T. TECVAYLI and ELREXFIO are off-the-shelf BCMA bispecific antibodies; TALVEY targets GPRC5D. Physicians also sequence antibody-drug conjugates, conventional regimens and clinical trials according to prior exposure, fitness, access and center capacity.

CARVYKTI’s randomized efficacy and growing earlier-line label are major advantages. Its disadvantages are patient-specific manufacturing, treatment-center dependence, time to infusion and acute/late safety monitoring. Bispecifics can start more quickly and do not require bespoke manufacturing, but have their own continuous-dosing, infection and response-duration tradeoffs.

LB2501 attacks the industry’s most important structural constraint: manufacturing outside the patient. It also enters a competitive field of in vivo gene delivery, allogeneic cell therapy and next-generation antibodies. Success will require more than a high response rate; platform manufacturability, vector safety and regulatory reproducibility will determine its competitive position.

13 Market data, ADR math and valuation framework

At the September 1, 2026 close of $21.13, per Marketstack, multiplying price by all 387.5 million ordinary shares produces an incorrect market capitalization because one Nasdaq ADS represents two ordinary shares. The correct basic ADS-equivalent count is approximately 193.77 million, implying an equity value near $4.09 billion. At the September 30, 2026 close of $19.89 the same arithmetic gives about $3.85 billion.

Subtracting $964.6 million of cash and time deposits produces a simple cash-adjusted value near $3.01 billion. Adding the $156.4 million collaboration advanced-funding liability gives an adjusted enterprise-style value near $3.16 billion before lease liabilities. Repeating both steps on the September 30 close gives about $2.89 billion cash-adjusted and about $3.05 billion on the adjusted enterprise-style basis. The cash figure is at June 30 and the price is at September 30, so the comparison is indicative rather than a balance-sheet measurement. These are orientation calculations, not formal target prices.

A headline price-to-earnings ratio is not yet robust: Q2 included a $56 million milestone, the tax arrangement remains unresolved and H1 still recorded a net loss. The cleaner framework values the CARVYKTI profit stream, then adds risk-adjusted pipeline and net financial resources.

14 Retail sentiment and attention

The live Stocktwits stream is useful as an attention gauge, not research. At the August 11, 2026 review the public page did not expose reliable numerical sentiment or message-volume scores, and none were invented then. The service has since begun returning them, and the figures below are its readings of September 30, 2026, with the September 2 readings kept beside them for comparison.

15 Catalyst and execution timeline

Calendar addition · September 10: September 23, 13:00–14:00 Rome: PA-199 safety study; September 25, 13:00–14:00 Rome: PA-288 CARTITUDE-2. IMS September 23–26 also includes PA-174 real-world evidence. Details and evidence limits.

A registry estimate or broad half-year window is not a confirmed catalyst.

16 Quarterly thesis checklist

17 Principal risks

• Single-product concentration: virtually all current commercial value is tied to CARVYKTI.
• Partner dependence: Janssen controls important development, manufacturing and commercialization functions; collaboration accounting reduces transparency versus wholly owned product sales.
• Safety: serious immune, neurologic, hematologic, gastrointestinal and secondary-malignancy risks can affect adoption and labels.
• Manufacturing: autologous capacity, release, logistics and treatment-center slots can limit growth even when demand is strong.
• Clinical extrapolation: six high-dose LB2501 patients and short follow-up cannot support mature probability assumptions.
• Competition: CAR-Ts, bispecifics and new myeloma regimens can change sequencing, price and eligible duration.
• Dilution: the June offering expanded the share base; future platform investment can require more capital.
• Tax/accounting: milestones and the unresolved transfer-pricing APA can make earnings volatile.
• Leadership: global scaling now proceeds under newly appointed CEO Ingrid Zhang.
• Foreign-private-issuer structure: IFRS reporting, ADS mechanics, China-related operations and GenScript control require additional governance diligence.

18 Merlintrader bottom line

Legend’s Q2 numbers establish a real commercial inflection: CARVYKTI trade sales grew 50%, reported revenue rose to $387.5 million and the company produced $33.2 million of net income. This is a materially stronger foundation than a typical early-stage cell-therapy company.

The next-platform narrative deserves interest and restraint in equal measure. LB2501 may address the central access and manufacturing limits of conventional CAR-T, and six high-dose responses with five complete responses are difficult to ignore. But six patients and 2.2 months of median follow-up cannot carry a multi-billion-dollar valuation conclusion.

The clean thesis is that CARVYKTI alone can justify most of the enterprise value if global adoption, manufacturing and collaboration economics continue improving, while LB2501 and other assets provide risk-adjusted upside. The clean bear case is that a single complex therapy, a partner-dependent profit stream, meaningful safety burden and recurring capital needs deserve a durable discount. The next decisive scorecards are Q3 trade sales and cash conversion, new-CEO execution, and larger, longer LB2501 data.

19 What the trial registry says about the frontline programmes

The catalyst table above notes that no CARTITUDE topline date has been stated by the company. That remains true, and the registry is not a substitute for company guidance. It is, however, a primary record, and on the sponsors’ own filed estimates it says something the summary does not.

Three things follow. The first is scale: 743 and 759 participants are large trials by myeloma standards, and both are fully enrolled rather than recruiting, which removes enrolment risk from the timeline and replaces it with follow-up time. The second is the horizon. A primary completion estimate of 2029 for CARTITUDE-5 and 2033 for CARTITUDE-6 is the date on which the primary endpoint is expected to be measured, not the date data are released, and sponsor estimates move. Even so, the order of magnitude is clear: the frontline expansion of CARVYKTI is a question for the end of this decade, not for the next two years, and any valuation that discounts frontline revenue into 2027 or 2028 is discounting something the registry does not support.

The third is ownership. CARTITUDE-6 is sponsored by the Stichting European Myeloma Network rather than by Janssen, a different governance arrangement from the rest of the programme, and one that puts control of the timeline outside the commercial partner.

The near-term value of Legend therefore rests where the revenue already is: on the relapsed and refractory setting, on manufacturing capacity and on the pace at which treatment sites are added. That is also where the company’s own disclosures are most specific.

20 The neurological safety file, and why it is a commercial variable

CAR-T therapy in myeloma carries a category of adverse events that does not appear in the usual oncology risk list, and for CARVYKTI it is the part of the label that most directly shapes where the therapy can be given and how quickly a treatment centre can be brought online. According to PubMed, the published evidence on this has grown considerably in 2026, and it points in a more manageable direction than the early data did.

What the trials reported. A review of the CARTITUDE programme covering more than 300 patients, published in Clinical Lymphoma, Myeloma & Leukemia (DOI 10.1016/j.clml.2026.04.013), reports cranial nerve palsy in 6.3% of patients overall, with a median onset on day 22 after infusion and complete recovery in 90% of cases. Immune effector cell parkinsonism, the movement and neurocognitive toxicity that drew most of the early attention, had a median onset at day 56. The two toxicities move in opposite directions with treatment burden, and that detail is easy to get wrong. Cranial nerve palsy was less frequent in the more heavily pretreated group, 3% against 9% in patients with one to three prior lines. Parkinsonism ran the other way: 1% in the one to three prior-lines group against 6% in the heavily pretreated group. High CAR-T cell expansion is associated with increased risk of both, and absolute lymphocyte count in the days 10 to 28 window correlates strongly enough with circulating CAR-T levels to be under investigation as an early trigger for pre-emptive steroids.

What routine practice reports. A retrospective study across two large United States databases, published in Oncology and Therapy (DOI 10.1007/s40487-026-00433-y), followed patients treated outside trials. In those with one to three prior lines, cranial nerve palsy occurred in 5.6% and 5.1% of patients in the two databases over a median follow-up of about three and a half months, with no parkinsonism and no Guillain-Barre syndrome observed. In those with four or more prior lines, followed for about thirteen months, parkinsonism occurred in 1.0% in both databases. The authors describe the real-world rates as comparable to or lower than the trials.

Why this belongs in an investment page rather than a clinical one. The neurological profile is what determines how far CARVYKTI can travel from academic centres toward community and outpatient settings, and that reach is the difference between a therapy used at a few hundred sites and one used at a few thousand. A single-centre account of implementation practice, published in Frontiers in Oncology (DOI 10.3389/fonc.2026.1841031), makes the operational side explicit: patient selection, structured workflows, multidisciplinary coordination and early referral pathways are what make the therapy deliverable outside a research setting. The same paper cites CARTITUDE-1 median overall survival of 60.7 months, with 33% of patients progression-free at five years or more.

The qualification. Real-world follow-up in the one to three prior-lines group is still short, around three and a half months in the database study, and parkinsonism in the trials had a median onset at day 56 with cases recognised later. Absence over a short window is not the same as absence. What can be said is that the accumulating evidence has not produced a worse picture than the trials did, which for a therapy whose commercial ceiling depends on where it can safely be administered is the direction that matters.

Related Merlintrader research

• Biotech Radar July 27, 2026 — the Legend CEO transition in context.
• Biotech Stocks Hub 2026 — company hubs and biotech research.
• Free Biotech Catalyst Calendar — FDA, PDUFA and clinical-event tracking.
• Biotech Catalyst Trading Guide — evidence, timing and valuation discipline.